NEW YORK – Genialis said on Wednesday that it has entered into data partnerships with Sidra Medicine of Qatar and Sapien Biosciences of India.

纽约——Genialis周三表示，已与卡塔尔的Sidra Medicine和印度的Sapien Biosciences建立数据合作关系。

The partnerships provide the RNA biomarker firm with new datasets representing patients from Qatar, India, and Asia more broadly. In a statement, Genialis said the data would help it validate biomarkers on diverse patient populations 'to better predict responses to KRAS inhibitors, immunotherapies, and other emerging classes of therapeutics.'.

这些合作关系为RNA生物标志物公司提供了代表卡塔尔，印度和亚洲更广泛患者的新数据集。Genialis在一份声明中表示，这些数据将有助于验证不同患者群体的生物标志物，“以更好地预测对KRAS抑制剂，免疫疗法和其他新兴疗法的反应。”。

'Sidra Medicine is committed to enhancing its research and pediatric cancer care program as part of our mission to provide precision medicine for all our patients in Qatar,' Wouter Hendrickx, lead PI of the Precision Oncology Initiative at Sidra Medicine, said in a statement. 'By integrating Genialis' suite of predictive biomarker algorithms into our workflows, we can begin to truly understand the molecular diversity of our patients and personalize treatment protocols and therapies.'.

Sidra Medicine精准肿瘤学倡议首席PI Wouter Hendrickx在一份声明中说：“作为我们为卡塔尔所有患者提供精准医学的使命的一部分，Sidra Medicine致力于加强其研究和儿科癌症护理计划。”通过将Genialis的一套预测性生物标志物算法整合到我们的工作流程中，我们可以开始真正了解患者的分子多样性，并个性化治疗方案和疗法。”。

Genialis, based in Ljubljana, Slovenia and Boston, has been developing RNA biomarker models for use in cancer diagnostics and drug discovery. It announced $13 million in Series A funding in March 2023 and a partnership with Cancer Research UK and Cancer Research Horizons to validate its therapy response prediction model last October.

Genialis位于卢布尔雅那、斯洛文尼亚和波士顿，一直在开发用于癌症诊断和药物发现的RNA生物标志物模型。它于2023年3月宣布了1300万美元的A系列资金，并于去年10月与英国癌症研究所和癌症研究地平线合作，以验证其治疗反应预测模型。

.

.

'Through these new data partnerships, we can incorporate data from all over the world into our modeling process,' Genialis CEO Rafael Rosengarten said in a statement. 'We're confident this will help us ​​deliver biomarkers that work for real patients and hopefully begin to close the gap in healthcare outcomes.'.

Genialis首席执行官拉斐尔·罗森加滕（RafaelRosengarten）在一份声明中说，通过这些新的数据合作关系，我们可以将来自世界各地的数据纳入我们的建模过程我们相信这将有助于我们​​提供适用于真实患者的生物标志物，并有望开始缩小医疗保健结果的差距。”。